Japan-based drug giant, Chugai pharmaceuticals to invest S$476 million in Singapore

2
2713

Singaporejapan flag

Japan-based Chugai pharmaceuticals recently announced that the company plans to invest nearly S$476 million into its research institute in Singapore-Chugai Pharmabody Research (CPR) from now until 2021. The company is to invest this huge amount of money to foster and accelerate research and development of new therapeutic antibodies. The company said in a statement that the additional investment will make the centre, one of the largest pharmaceutical operation in Singapore.

Mr Koichi Matsubara, director and CEO of Chugai pharmaceuticals, said that the research institute also planned to increase its strength by 40 researchers by 2016. The institute currently employs around 70 people with expertise in developing antibody drugs using Chugai innovatory platforms.

Mr Lim Chuan Poh, chairman of A*STAR,Singapore, said that Chugai’s expansion in Singapore shows Singapore’s attractiveness as a biotech hub with ready access to biomedical research talent, state-of-the-art infrastructure, and an environment that encourages open innovation through partnerships.

This article is based on materials provided by:

http://bit.ly/1DYdl0r

Previous articleDeep Insights into the Mudskipper genomes! -A species new to Whole Genome sequencing (WGS)
Next articleShedding light on the inner circuits of the brain
Scientist-entrepreneur-manager-journalist: -Co-founder, Author; Former Assistant Editor and Director, Biotechin.Asia, Biotech Media Pte. Ltd.; -Founder & CEO, SciGlo (www.sciglo.com); -Programme Management Officer, SBIC, A*STAR (former Research Fellow). --Sandhya graduated from University of Madras, India (B.Sc Microbiology and M.Sc Biotechnology) and received her Ph.D from the Nanyang Technological University, Singapore. She worked on oxidative stress in skin, skeletal, adipose tissue and cardiac muscle for a decade from 2006-2016. She is currently working as a Programme Management Officer handling projects and grants at Singapore Bioimaging Consortium (SBIC), Agency for Science, Technology and Research (A*STAR). Earlier to this she was a Research Fellow in the Fat Metabolism and Stem Cell Group at SBIC. Sandhya was also the Vice President and Publicity Chair of A*PECSS (A*STAR Post Doc Society) (2014-2016). Recently she founded a platform for scientists - SciGlo (www.sciglo.com) and is a startup mentor at Vertical VC (Finland). She is an ardent lover of science and enjoys globe trotting and good vegetarian food.